Compare Biogen Inc (BIIB) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Essex Property Trust, Inc. — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Essex Property Trust, Inc. trades at $282.11 (market cap $18.15B). The key difference: Biogen Inc is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | ESS | |
|---|---|---|
Market Cap | $30.13B | $18.15B |
Sector | Health | Real Estate |
52-Week High | $216.63 | $298.33 |
52-Week Low | $128.93 | $239.61 |
Enterprise Value | $37.20B | $24.75B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
ESS trades at $281.27, down 0.69% on the day, with a bearish technical signal. The company reported a Q2 2026 EPS miss ($0.97 vs. $1.46 expected) but raised full-year FFO guidance. Revenue grew to $1.89B in 2025, with a strong net income margin of 35.48%, though profitability is projected to moderate in 2026. The stock is supported by a $2.59 dividend and a consensus price target of $305.86, implying potential upside.
The outlook is mixed: raised guidance and institutional buying signal confidence, but technical weakness and a high debt load pose risks. The stock offers income and growth potential if operational execution improves, yet faces headwinds from regional market softness and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
